Skip to main content
AI Search Assistant Beta
English
中文
Log In
Log in
Log in with ORCID
NTU Single Sign On
Have you forgotten your password?
Home
.National Taiwan University / 國立臺灣大學
Project / 研究計畫
Optimization of Anti-Mycobacterial Therapy among Patients with Anti-Interferon-Gamma Autoantibodies through Therapeutic Drug Monitoring (Extended Study) (II) = 抗丙型干擾素自體抗體病人使用抗分枝桿菌藥物之療效監測與精準劑量探討 (延伸研究) (II)
Optimization of Anti-Mycobacterial Therapy among Patients with Anti-Interferon-Gamma Autoantibodies through Therapeutic Drug Monitoring (Extended Study) (II) = 抗丙型干擾素自體抗體病人使用抗分枝桿菌藥物之療效監測與精準劑量探討 (延伸研究) (II)
Details
Primary Data
Project title
抗丙型干擾素自體抗體病人使用抗分枝桿菌藥物之療效監測與精準劑量探討 (延伸研究) (II)
Internal ID
NSTC113-2314-B002-121
Principal Investigator
UN-IN WU
Start Date
August 1, 2024
End Date
July 31, 2025
Investigators
YEE-CHUN CHEN
JANN-TAY WANG
SHU-WEN LIN
林綺英
楊家瑞
WANG-HUEI SHENG
Organizations
Medicine-NTUCC
Partner Organizations
National Science and Technology Council
Description
Keywords
Anti-interferon-gamma autoantibodies
Nontuberculous mycobacterial infection
Therapeutic drug monitoring
Adverse drug reactions
Description
1. 創新性:目前國內外有關免疫缺損病人之分枝桿菌治療缺乏實證,且現今國際指引絕大多數皆建立在專家意見之基礎上,本研究結果除可深入與各國分享我國經驗外,預期亦可成為未來分枝桿菌藥物治療國際指引之參考依據。 2.重要性:分枝桿菌的感染發生率逐年提高,於許多國家其盛行率已超過結核病。本研究結果不僅能提供目前抗丙型干擾素自體抗體病人分枝桿菌感染之TDM目標值及合適劑量調整方法等治療準則,同時也可作為其他患有分枝桿菌感染之免疫缺損病人之重要治療依據。 3.可行性:本團隊具有嫻熟之樣本採檢與療效及藥物副作用等監測流程,除將有助於抗丙型干擾素自體抗體病人之標準臨床照顧模式之建置外,亦可成功達成預期目標。
Show more